引用次数
引用: 913
H-指数: 14
I10-指数 : 21
出版物: 84
Benefit/ris k communication by the European Medicines Agency: a study of influential stakeholders' expectations and attitudes
Frederic Bouder
11
2011
When ‘Must’ Means ‘Maybe’: Varieties of Risk Regulation and the Problem of Trade-offs in Europe. HowSAFE Working Paper, No. 1
David Burgess Demeritt , Olivier Borraz , Michael Huber , Henry Frederick Rothstein
4
2015
The Risks of the Mask
Frederic Bouder , Matan Shapiro
Journal of Risk Research 24 492 -505
2021
Risk Perception and Communication
Frederic Bouder
Improving Disaster Resilience and Mitigation - IT Means and Tools 45 -62
2
2014
Regulating impurities in pharmaceutical products: a tolerability of risk approach?
Frederic Bouder
Expert Review of Clinical Pharmacology 1 ( 2) 241 -250
19
2008
Tolerability of risk approach and the management of pharmaceutical risks.
Frederic Bouder , Ragnar Löfstedt
Expert Review of Clinical Pharmacology 1 ( 2) 187 -190
2
2008
Transparency and the Food and Drug Administration—A Quantitative Study
Ragnar Lofstedt , Frederic Bouder , Sweta Chakraborty
Journal of Health Communication 18 ( 4) 391 -396
10
2013
Varieties of risk regulation in Europe: coordination, complementarity and occupational safety in capitalist welfare states
Henry Rothstein , David Demeritt , Regine Paul , Anne-Laure Beaussier
Socio-economic Review 17 ( 4) 993 -1020
9
2019
Risk Communication of Vaccines: Challenges in the Post-Trust Environment
Frederic Bouder
Current Drug Safety 10 ( 1) 9 -15
8
2015
The Future of Risk Communication and the Role of the Pharmaceutical Industry
Sweta Chakraborty , Frederic Bouder
Current Drug Safety 8 ( 1) 4 -10
7
2013
Can practitioners communicate risks better? Learning from evidence to develop best practice.
Frederic Bouder
European journal of risk regulation 3 ( 1) 280 -285
2010
Does hazard-based Communication work?
Frederic Bouder
European journal of risk regulation 2 ( 02) 173 -175
2011
The Diva and Destiny: Can the Voter be Appeased with Fatalism?
Michel van Eeten , Frederic Bouder
European journal of risk regulation 3 ( 3) 293 -303
3
2012
The Ditchley Transparency Manifesto
Frederic Bouder , Ragnar Lofstedt
Drug Information Journal 46 ( 1) 7 -7
2
2012
Pharmaceutical Benefit–Risk Communication Tools: A Review of the Literature
Dominic Way , Hortense Blazsin , Ragnar Löfstedt , Frederic Bouder
Drug Safety 40 ( 1) 15 -36
16
2017
Unmasking Environmental Health Zorros: The Need for Involvement of Real Risk Communication Experts for Two-Way and Problem-Solving Communication Approaches
Hans Keune , Peter Van Den Hazel , Frederic Bouder
Environmental Determinants of Human Health 203 -224
2016
Transparency in Europe: A Quantitative Study
Frederic Bouder , Dominic Way , Ragnar Löfstedt , Darrick Evensen
Risk Analysis 35 ( 7) 1210 -1229
33
2015
The changing nature of communication and regulation of risk in Europe
Ragnar Lofstedt , Frederic Bouder , Jamie Wardman , Sweta Chakraborty
Journal of Risk Research 14 ( 4) 409 -429
63
2011
Transparency of medicines data and safety issues - a European/US study of doctors' opinions: what does the evidence show?
Ragnar Löfstedt , Dominic Way , Frederic Bouder , Darrick Evensen
Journal of Risk Research 19 ( 9) 1172 -1184
7
2016
Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients
Dominic Way , Frederic Bouder , Ragnar Löfstedt , Darrick Evensen
Journal of Risk Research 19 ( 9) 1185 -1215
16
2016